{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:36:00Z","timestamp":1780497360251,"version":"3.54.1"},"reference-count":46,"publisher":"Gobierno de Navarra","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"DOI":"10.23938\/assn.1065","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:31:26Z","timestamp":1717137086000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of high-risk human papillomavirus genotyping for cervical cancer screening. A multicentre screening cohort study in rural China"],"prefix":"10.23938","volume":"47","author":[{"given":"Yan-Qin","family":"Yu","sequence":"first","affiliation":[{"name":"National Cancer Center \/National Clinical Research Center for Cancer\/Cancer Hospital. yanqinyu2022@163.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yue","family":"Jiang","sequence":"additional","affiliation":[{"name":"National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. jiang.my@163.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. zhangxun7508@163.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Jing","family":"Pan","sequence":"additional","affiliation":[{"name":"National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. pqjing@hotmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Dang","sequence":"additional","affiliation":[{"name":"National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. dangle0610@126.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Mei","family":"Feng","sequence":"additional","affiliation":[{"name":"2 National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. ruimei_feng@163.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naasra Mohamoud","family":"Ali","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University. Department of Oncology. Dalian. China. yanqin0324@126.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Baotou Medical College\/Clinical Epidemiology Research Centre of The First Affiliated Hospital of Baotou Medical College. Department of Public Health and Preventive Medicine. Baotou. China. chenwen@cicams.ac.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Lin","family":"Qiao","sequence":"additional","affiliation":[{"name":"National Cancer Centre \/National Clinical Research Centre for Cancer\/Cancer Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Department of Cancer Epidemiology. Beijing. China. qiaoy@cicams.ac.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10024","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I, JEMAL A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. XIA C, DONG X, LI H, CAO M, SUN D, HE S et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135(5): 584-590. https:\/\/doi.org\/10.1097\/CM9.0000000000002108","DOI":"10.1097\/CM9.0000000000002108"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. TERASAWA T, HOSONO S, SASAKI S, HOSHI K, HAMASHIMA Y, KATAYAMA T et al. Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis. Sci Rep 2022; 12(1): 94. https:\/\/doi.org\/10.1038\/s41598-021-04201-y","DOI":"10.1038\/s41598-021-04201-y"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. BONDE JH, SANDRI MT, GARY DS, ANDREWS JC. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J Low Genit Tract Dis 2020; 24(1): 1-13. https:\/\/doi.org\/10.1097\/LGT.0000000000000494","DOI":"10.1097\/LGT.0000000000000494"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. BUCCHI L, BALDACCHINI F, MANCINI S, RAVAIOLI A, GIULIANI O, VATTIATO R et al. Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy. Int J Cancer. 2019; 144(5): 1017-1026. https:\/\/doi.org\/10.1002\/ijc.31806","DOI":"10.1002\/ijc.31806"},{"key":"ref5","unstructured":"6. BAO HL, FANG LW, WANG LH. Current situation and strategic thinking of establishing cervical cancer prevention and control system in the world. Chinese Journal of Preventive Medicine 2017; 51 (1): 96-100."},{"key":"ref6","unstructured":"7. ZHAO YQ, DAI Y, DANG L, KONG LH, ZHANG Y, FENG RM et al. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population]. Zhonghua Zhong Liu Za Zhi. 2018; 40(10): 764-771. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.10.008"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. CHUA BWB, MA VY, ALC\u00c1NTAR-FERN\u00c1NDEZ J, WEE HL. Is it time to genotype beyond HPV16 and HPV18 for cervical cancer screening? Int J Public Health 2022; 67: 1604621. https:\/\/doi.org\/10.3389\/ijph.2022.1604621","DOI":"10.3389\/ijph.2022.1604621"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. CASTLE PE, STOLER MH, WRIGHT TC JR, SHARMA A, WRIGHT TL, BEHRENS CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12(9): 880-890. https:\/\/doi.org\/10.1016\/S1470-2045(11)70188-7","DOI":"10.1016\/S1470-2045(11)70188-7"},{"key":"ref9","unstructured":"10. ZHAO YX, MA L, REN WH, SONG B, WANG LH, DI JL, WU JL. Analysis of the reported data of national cervical cancer screening program in rural areas in China from 2009 to 2018. Zhonghua Yi Xue Za Zhi 2021; 101: 1863-1868. doi:10.3760\/cma.j.cn112137-20210111-00075"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. OGILVIE GS, VAN NIEKERK D, KRAJDEN M, SMITH LW, COOK D, GONDARA L et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA 2018; 320(1): 43-52. https:\/\/doi.org\/10.1001\/jama.2018.7464","DOI":"10.1001\/jama.2018.7464"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. SMITH MA, SHERRAH M, SULTANA F, CASTLE PE, ARBYN M, GERTIG D et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ 2022; 376: e068582. https:\/\/doi.org\/10.1136\/bmj-2021-068582","DOI":"10.1136\/bmj-2021-068582"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. DEL MISTRO A, ADCOCK R, CAROZZI F, GILLIO-TOS A, DE MARCO L, GIRLANDO S et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. Int J Cancer 2018; 143(2): 333-342. https:\/\/doi.org\/10.1002\/ijc.31326","DOI":"10.1002\/ijc.31326"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. KUROKAWA T, YOSHIDA Y, IWANARI O, OISHI T, KASAI T, HAMADA M et al. Implementation of primary HPV testing in Japan. Mol Clin Oncol 2020; 13(4): 22. https:\/\/doi.org\/10.3892\/mco.2020.2092","DOI":"10.3892\/mco.2020.2092"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. ELFSTR\u00d6M KM, EKLUND C, LAMIN H, \u00d6HMAN D, HORTLUND M, ELFGREN K et al. Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial. PLoS Med 2021; 18(8): e1003748. https:\/\/doi.org\/10.1371\/journal.pmed.1003748","DOI":"10.1371\/journal.pmed.1003748"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. BEDELL SL, GOLDSTEIN LS, GOLDSTEIN AR, GOLDSTEIN AT. Cervical cancer screening: past, present, and future. Sex Med Rev 2020; 8(1): 28-37. https:\/\/doi.org\/10.1016\/j.sxmr.2019.09.005","DOI":"10.1016\/j.sxmr.2019.09.005"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. ZHANG J, ZHAO Y, DAI Y, DANG L, MA L, YANG C et al. Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open-label, randomized clinical trial. JAMA Oncol 2021; 7(2): 263-270. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6575","DOI":"10.1001\/jamaoncol.2020.6575"},{"key":"ref17","unstructured":"18. WANG H L, YANG X, LI Y B, YU H, FEI XD. Application of standardized patients in job training of rural obstetrician and gynecologists. China Health Industry 2011; 8(34): 129-130. https:\/\/doi.org\/10.16659\/j.cnki.1672-5654.2011.34.016"},{"key":"ref18","unstructured":"19. ZHU T. The clinical value of TCT and HPV examination combined with colposcopy for cervical cancer screening. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine 2020; 30(17): 72-73. https:\/\/doi.org\/10.16458\/j.cnki.1007-0893.2020.17.036"},{"key":"ref19","unstructured":"20. ZHAO J. [The results of cervical cancer screening among 16408 rural women in Gujiao city were analyzed by different detection methods]. Chinese Drug and Clinical 2021; 21(09): 1596-1598. https:\/\/doi.org\/10.11655\/zgywylc2021.09.068"},{"key":"ref20","unstructured":"21. WANG Y, WANG D, YEERJIANG KAYM, TALEHATI DDE, CHI Y, LIU L et al. Screening effect of self-sampling HPV detection as an alternative to cervical cancer screening in areas lacking health resources in Xinjiang. Advances in Modern Obstetrics and Gynecology 2023; 32(02): 90-94."},{"key":"ref21","unstructured":"22. LIAN W, SU X. Effect of positive fluid-based cytology on screening for cervical lesions. Journal of Chronic Diseases 2023; 24(01): 65-67. https:\/\/doi.org\/10.16440\/J.CNKI.1674-8166.2023.01.17"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. CANFELL K, SAVILLE M, CARUANA M, GEBSKI V, DARLINGTON-BROWN J, BROTHERTON J et al. Protocol for compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. BMJ Open 2018; 8(1): e016700. https:\/\/doi.org\/10.1136\/bmjopen-2017-016700","DOI":"10.1136\/bmjopen-2017-016700"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. XUE P, GAO LL, YIN J, HAN LL, ZHAO J, LI L et al. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: detecting CIN2+ in low-resource settings. J Med Virol 2019; 91(7): 1342-1350. https:\/\/doi.org\/10.1002\/jmv.25451","DOI":"10.1002\/jmv.25451"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. CHRYSOSTOMOU AC, KOSTRIKIS LG. Methodologies of primary HPV testing currently applied for cervical cancer screening. Life (Basel) 2020; 10(11): 290. https:\/\/doi.org\/10.3390\/life10110290","DOI":"10.3390\/life10110290"},{"key":"ref25","unstructured":"26. YANG L, LIU D, WANG F. Application of fluid-based cytology combined with colposcopy in cervical cancer screening. Journal of North Sichuan Medical College 2023; 38(02): 262-264."},{"key":"ref26","unstructured":"27. ZHAO S, CHEN H, ZHAO FH. [Global guidelines for cervical cancer and precancerous lesions treatment: a systematic review]. Zhonghua Yi Xue Za Zhi 2022; 102(22): 1666-1676. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20211106-02466"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. KOMBE KOMBE AJ, LI B, ZAHID A, MENGIST HM, BOUNDA GA et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health 2021; 8: 552028. https:\/\/doi.org\/10.3389\/fpubh.2020.552028","DOI":"10.3389\/fpubh.2020.552028"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. LIU L, WANG D, DONG H, JIN C, JIANG L, SONG H et al. Characteristics of carcinogenic HPV genotypes in north China plain and the association with cervical lesions. Medicine (Baltimore) 2019; 98(37): e17087. https:\/\/doi.org\/10.1097\/MD.0000000000017087","DOI":"10.1097\/MD.0000000000017087"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. GILHAM C, SARGENT A, KITCHENER HC, PETO J. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess 2019; 23(28): 1-44. https:\/\/doi.org\/10.3310\/hta23280","DOI":"10.3310\/hta23280"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. \u015eAHIN D, KO\u00c7 N, AKBA\u015e M. Effects of an additional liquid based cytology prepate on cytological diagnosis in high-risk HPV positive, PaP Test Negative Cases. Sisli Etfal Hastan Tip Bul 2019; 53(4): 361-365. https:\/\/doi.org\/10.14744\/SEMB.2019.23434","DOI":"10.14744\/SEMB.2019.23434"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. ZHONG G, WANG Y, XIE Q, LIN R, YAO T. HPV-specific risk assessment of cervical cytological abnormalities. BMC Cancer 2021; 21(1): 949. https:\/\/doi.org\/10.1186\/s12885-021-08703-w","DOI":"10.1186\/s12885-021-08703-w"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. YANG H, LI SP, CHEN Q, MORGAN C. Barriers to cervical cancer screening among rural women in eastern China: a qualitative study. BMJ Open 2019; 9(3): e026413. https:\/\/doi.org\/10.1136\/bmjopen-2018-026413","DOI":"10.1136\/bmjopen-2018-026413"},{"key":"ref33","unstructured":"34. ZHAO Y, ZHAO F, HU S, CHEN W, CHEN F, CUI J et al. [Multi-center cross-sectional study on type-specific human papillomavirus infection among Chinese women]. Zhonghua Liu Xing Bing Xue Za Zhi 2015; 36(12): 1351-1356."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. ZHANG J, CHENG K, WANG Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Arch Gynecol Obstet 2020; 302(6): 1329-1337. https:\/\/doi.org\/10.1007\/s00404-020-05787-w","DOI":"10.1007\/s00404-020-05787-w"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. YAN X, HUANG Y, ZHANG M, HU X, LI K, JING M. Prevalence of human papillomavirus infection and type distribution among Uyghur females in Xinjiang, northwest China. Oncol Lett 2020; 20(4): 25. https:\/\/doi.org\/10.3892\/ol.2020.11886","DOI":"10.3892\/ol.2020.11886"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. PETRY KU, COX JT, JOHNSON K, QUINT W, RIDDER R, SIDERI M et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer 2016; 138(12): 2932-2939. https:\/\/doi.org\/10.1002\/ijc.30032","DOI":"10.1002\/ijc.30032"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. STOLER MH, WRIGHT TC JR, PARVU V, VAUGHAN L, YANSON K, ECKERT K et al. The onclarity human papillomavirus trial: design, methods, and baseline results. Gynecol Oncol 2018; 149(3): 498-505. https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.007","DOI":"10.1016\/j.ygyno.2018.04.007"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. WANG Z, LI Z, LI J, WANG C, WANG W, HAO M et al. Prevalence and distribution of HPV genotypes in 1387 women with cervical intraepithelial neoplasia 2\/3 in Shanxi province, China. J Cancer 2018; 9(16): 2802-2806. https:\/\/doi.org\/10.7150\/jca.25614","DOI":"10.7150\/jca.25614"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. FENG RM, WANG M, SMITH JS, DONG L, CHEN F, PAN QJ et al. Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China. J Clin Virol 2018; 99-100: 84-90. https:\/\/doi.org\/10.1016\/j.jcv.2017.12.015","DOI":"10.1016\/j.jcv.2017.12.015"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. ST-MARTIN G, THAMSBORG LH, ANDERSEN B, CHRISTENSEN J, EJERSBO D, JOCHUMSEN K et al. Management of low-grade cervical cytology in young women. Cohort study from Denmark. Acta Oncol 2021; 60(4): 444-451. https:\/\/doi.org\/10.1080\/0284186X.2020.1831061","DOI":"10.1080\/0284186X.2020.1831061"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. WOODMAN CB, COLLINS S, WINTER H, BAILEY A, ELLIS J, PRIOR P et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357(9271): 1831-1836. https:\/\/doi.org\/10.1016\/S0140-6736(00)04956-4","DOI":"10.1016\/S0140-6736(00)04956-4"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. CHEUNG LC, EGEMEN D, CHEN X, KATKI HA, DEMARCO M, WISER AL et al. 2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. J Low Genit Tract Dis 2020; 24(2): 90-101. https:\/\/doi.org\/10.1097\/LGT.0000000000000528","DOI":"10.1097\/LGT.0000000000000528"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. DEMARCO M, EGEMEN D, RAINE-BENNETT TR, CHEUNG LC, BEFANO B, POITRAS NE et al. A study of partial human papillomavirus genotyping in support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020; 24(2): 144-147. https:\/\/doi.org\/10.1097\/LGT.0000000000000530","DOI":"10.1097\/LGT.0000000000000530"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. SHI JF, BELINSON JL, ZHAO FH, PRETORIUS RG, LI J, MA JF et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. Am J Epidemiol 2009; 170(6): 708-716. https:\/\/doi.org\/10.1093\/aje\/kwp188","DOI":"10.1093\/aje\/kwp188"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. SCHIFFMAN M, KINNEY WK, CHEUNG LC, GAGE JC, FETTERMAN B, POITRAS NE et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst. 2018; 110(5): 501-508. https:\/\/doi.org\/10.1093\/jnci\/djx225","DOI":"10.1093\/jnci\/djx225"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/101966\/78212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T10:48:58Z","timestamp":1747133338000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/101966\/78212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,31]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.1065","relation":{},"ISSN":["2340-3527"],"issn-type":[{"value":"2340-3527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"article-number":"e1065"}}